- BNF:
- Not listed
- Status:
- Red
- Decision Date:
- December 2017
Comments
RED1,2,3: NICE TA485 - Sarilumab for moderate to severe rheumatoid arthritis. (Decision date - December 2017)
CCG commissioned drug.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again